FDA actions this week highlighted both the pace of modern oncology approvals and the political scrutiny around medical policy. Replimune’s oncolytic viral therapy Tudriqev received an accelerated nod for advanced melanoma after a path that included an initial FDA rejection and a quick advisory committee turnaround, positioning it as a more convenient option versus cell-therapy competitors in the same setting. Separately, BIOCENTURY reported that FDA regulatory moves are “reflecting a steadying ship,” citing approvals tied to Moderna and Replimune alongside Takeda’s narcolepsy therapy—an editorial framing of reduced controversy and clearer review outcomes. The parallel policy track also remained active: Democratic senators urged CMS to withdraw interim final Medicaid work requirements, arguing the rule adds administrative burden and threatens coverage for eligible beneficiaries. The combination of regulatory decisions and payer-policy pressure underscores how access outcomes can hinge on both drug review timelines and reimbursement rules.